Oncorus

Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. It develops an immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Andover, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur.  Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported fourth quarter and full year 2021 financial results and highlighted recent achievements and developments.

Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.

Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Jefferies London Healthcare Conference.

Oncorus to Present at the Jefferies London Healthcare Conference

Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors. ONCR-177 is a Herpes Simplex Virus (HSV) product candidate.

Why Did Oncorus Shares Slump To 52-Week Low Today?

The company announced initial data from a phase 1 study.

Why Oncorus Stock Is Crashing Today

Oncorus Inc (NASDAQ: ONCR) has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 (IL-12) via oncolytic viral expression in combination with an immune checkpoint inhibitor.  IL-12 is one of five immunomodulatory payloads in Oncorus' lead viral immunotherapy product candidate, ONCR-177.

Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement

The average of price targets set by Wall Street analysts indicates a potential upside of 200.7% in Oncorus, Inc. (ONCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 201% Upside in Oncorus, Inc. (ONCR): Here's What You Should Know

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported third quarter 2021 financial results and highlighted recent achievements and developments.

Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported second quarter 2021 financial results and highlighted recent achievements and developments.

Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights

-- Former Merck executive brings extensive experience in corporate development, licensing and  financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Barbara Yanni to fill a vacancy on its Board of Directors. Since her retirement from Merck & Co. in 2014, where she served as Vice President and Chief Licensing Officer, Ms. Yanni has served as a director of multiple publicly traded and privately held biopharmaceutical companies. She brings extensive experience in corporate development, licensing and financial evaluation to Oncorus, as the company advances its pipeline of intratumorally (iTu) administered oncolytic Herpes Simplex Virus immunotherapies and intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapies.

Oncorus Expands its Board with Appointment of Barbara Yanni

Oncorus shares have been in steady decline since nearly doubling in value less than six months after the company's October 2020 IPO. Current trading price of $13 is slightly under the $15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ONCR-177.

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Eric Rubin, M.D. to its Board of Directors. Dr. Rubin brings to Oncorus an expansive 30-year academic and industry career in cancer drug development, including his oncology leadership roles at Merck, known as MSD outside of the United States and Canada, where he currently serves as Senior Vice President of Global Clinical Oncology. As previously announced, the terms of Robert Kirkman, M.D. and Cameron Wheeler, Ph.D. as members of Oncorus' Board of Directors ended upon the conclusion of the company's annual meeting of stockholders held on June 16, 2021.

Oncorus Appoints Eric Rubin, M.D. to its Board of Directors

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it will host an upcoming investor day featuring its intravenous (IV)-administered Synthetic viral RNA (vRNA) Immunotherapy Platform, and its recently nominated lead Synthetic vRNA Immunotherapy product candidates, ONCR-021 and ONCR-788. The virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ET.

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the nomination of its first Synthetic viral RNA (vRNA) immunotherapy clinical candidates, ONCR-021 and ONCR-788. Oncorus' pioneering intravenous (IV)-administered approach involves encapsulating the genomes of RNA viruses known to kill cancer cells (i.e., oncolytic viruses, or OVs) in a lipid nanoparticle (or LNP), creating a Synthetic vRNA immunotherapy. ONCR-021 encodes an optimized strain of Coxsackievirus A21 (CVA21), and ONCR-788 encodes for a modified version of the Seneca Valley Virus (SVV). Both CVA21 and SVV have extensive clinical experience and favorable safety profiles when administered IV. Oncorus' novel Synthetic vRNA approach holds the potential for IV-administration and avoids the challenge of neutralizing antibodies seen in previous approaches with IV-administered OVs. Oncorus plans to investigate its novel Synthetic vRNA immunotherapies in multiple histologies including cancers of the lung both as monotherapy and in combination with immune checkpoint inhibitors and other cancer treatments.

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the upcoming Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:00 p.m. ET.

Oncorus to Present at Upcoming Jefferies Virtual Healthcare Conference

-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H'21 -- -- Company plans to nominate first two intravenously (IV) administered synthetic viral RNA (vRNA) immunotherapy candidates in 1H'21 --

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

The company is using engineered herpes simplex viruses and engineered synthetic viruses in oncology. The stock doubled after the IPO, then pulled back close to the IPO price and is rebounding.

Oncorus Inc.: Undervalued Cancer Viral Immunotherapy Opportunity

Bumble

Fiserv

Anterix Inc

Corvus Pharmaceuticals

Decibel Therapeautics

Molecular Templates

NexImmune

Prothena

Talis Biomedical

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Alphabet

Goldman Sachs

Limbach Holdings

PagerDuty

Unilever

Real Estate Select Sector SPDR Fund

These are 7 of the best swing trade stocks on the market right now, but you need to have a strategy and rules in order to be safe. The post 7 of the Best Swing Trade Stocks Available Right Now appeared first on InvestorPlace.

7 of the Best Swing Trade Stocks Available Right Now

Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on the last close price of $20.97 on Thursday.

Oncorus Secures $57M Via Equity At 9% Discount

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $19.00 per share. All shares of common stock in the offering are being offered by Oncorus. The gross proceeds to Oncorus from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $57.0 million. In addition, Oncorus has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 17, 2021, subject to satisfaction of customary closing conditions.

Oncorus Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Oncorus. In addition, Oncorus intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering price has not yet been determined. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Oncorus Announces Proposed Public Offering of Common Stock

Oncorus Inc.'s share price has risen by over 120% in about three months of listing. ONCR's novel technology is still a reason to consider the stock as an investment in emerging biopharmaceutical, but the upside seems to be limited from the current levels.

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its  five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor regression and protective antitumor memory observed in multiple syngeneic tumor models --

Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product  pipeline of intratumorally and intravenously administered viral immunotherapies –

News for Oncorus Stock (ONCR)